Physician profile
Bryan C Bunn
NPI 1568787141
$4,171.03
in general payments reported to CMS, 2019-2025
34 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $514 · 2021: $830 · 2022: $713 · 2023: $761 · 2024: $374 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,076.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.21 | 2019-2025 | Jardiance |
| Abbvie INC. | $381.63 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $288.52 | 2019-2025 | |
| Lilly USA, LLC | $219.29 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $150.33 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $145.40 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $123.93 | 2019-2022 | |
| Allergan, INC. | $121.38 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $118.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $106.33 | 2019-2023 | Xarelto |
| Amgen INC. | $95.02 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $94.46 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Bioventus LLC | $86.64 | 2022-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| E.R. Squibb & Sons, L.L.C. | $76.34 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $55.05 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $55.03 | 2019-2022 | |
| Esperion Therapeutics, INC. | $54.26 | 2021 | |
| Exact Sciences Corporation | $49.04 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $45.25 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $31.60 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $18.06 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.96 | 2021 | |
| Cranial Technologies, INC | $16.72 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.62 | 2023 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $16.46 | 2024 | Crysvita |
| Dynavax Technologies Corporation | $15.64 | 2022 | |
| Depuy Synthes Sales INC. | $15.50 | 2025 | Monovisc, Orthovisc |
| Biocryst US Sales Co., LLC | $15.02 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.72 | 2023 | Iovera, Exparel, Zilretta |
| Hartmann USA, INC. | $13.41 | 2023 | Zetuvit Plus |
| Avanos Medical | $13.18 | 2023 | Trivisc Sodium Hyaluronate |
| Eisai INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Bunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.